Company profile / ZIMLABORATORIES

Zim Laboratories

Other · 1 quarter tracked · source-linked performance and management context.

Research layer active
WatchDelivery assessment incompleteLatest record q3-fy26

Latest revenue

₹108.66 Cr

verified financial record

Quarters tracked

1

source records in the directory

Delivery assessment

Unscored

No scored management commitments are present yet.

Call date

2026-02-10

latest available source date

Signal trajectory

1 actual quarter
PAT (₹ Cr)PositiveWatchNegative
1 actual records
Actual quarterly PAT (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 4.4 · Watch source sentiment · 2026-02-10Q3 FY264.44.4
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

Unscored

No scored management commitments are present yet.

Latest source read

What changed this quarter?

Open quarter read

Zim Laboratories reported Q3 FY26 operating income of ₹1,087 crore, with EBITDA of ₹145 crore (13.4% margin) and PAT of ₹44 crore, showing sequential improvement. Export revenue surged 232% YoY to ₹961 crore, contributing 88% of revenue. The EUGMP remediation remains the top priority; management expects the audit in Q1 FY27 (April-June 2026). NIP product commercialization in regulated markets is delayed until EUGMP clearance, but emerging market traction continues. A preferential issue of ₹35 crore was completed to fund capex and compliance. Key risk: further delay in EUGMP audit could push back regulated market entry and NIP revenue inflection.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Watch

Revenue

₹108.66 Cr

Source date

2026-02-10

Across the record

Quarter history.

1 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary